2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 1
1
Status
Completed
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Leukemia, Myeloid, Acute
3
Leukemia
3
Vomiting
2
Stomach Neoplasms
2
Prostatic Neoplasms
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Motor Activity
2
Ventilator-Induced Lung Injury
1
Urologic Neoplasms
1
Urogenital Neoplasms
1
Substance-Related Disorders
1
Solid Tumors
1
Recurrence
1
Postoperative Complications
1
Pituitary Neoplasms
1
Pancreatic Neoplasms
1
Opioid-Related Disorders
1
Opioid-Induced Constipation
1
Neurofibromatosis 1
1
Neoplasms
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Lymphoma, Follicular
1
Lymphoma
1
Lung Neoplasms
1
Low Anterior Resection Syndrome
1
Kidney Neoplasms
1
Hematologic Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Interventions
Docetaxel
292
Prednisone
240
enzalutamide
193
Leuprolide
185
Radiotherapy
179
Abiraterone Acetate
169
Magnetic Resonance Spectroscopy
163
bicalutamide
141
Goserelin
138
Androgen Antagonists
121
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
108
Radiosurgery
108
apalutamide
92
gallium 68 PSMA-11
81
abiraterone
81
Specimen Handling
73
darolutamide
65
Surveys and Questionnaires
64
Gonadotropin-Releasing Hormone
63
Triptorelin Pamoate
58
Radiation
57
Biopsy
57
Brachytherapy
54
cabazitaxel
52
Standard of Care
51
Radiotherapy, Intensity-Modulated
51
Zoledronic Acid
50
pembrolizumab
49
luprolide acetate gel depot
49
Flutamide
47
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Prostatic Neoplasms
×
Dosage Forms
×
Clear all
NCT00913068
2021-10-04
TAP
Nova Scotia Health Authority
Phase NA
Completed
110 enrolled
5 charts
NCT01784757
2021-03-17
ARAFOR
Orion Corporation, Orion Pharma
Phase 1
Completed
30 enrolled